KR20150001757A - 기저 인슐린 요법 - Google Patents

기저 인슐린 요법 Download PDF

Info

Publication number
KR20150001757A
KR20150001757A KR20147028987A KR20147028987A KR20150001757A KR 20150001757 A KR20150001757 A KR 20150001757A KR 20147028987 A KR20147028987 A KR 20147028987A KR 20147028987 A KR20147028987 A KR 20147028987A KR 20150001757 A KR20150001757 A KR 20150001757A
Authority
KR
South Korea
Prior art keywords
insulin
diabetes
patient
type
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147028987A
Other languages
English (en)
Korean (ko)
Inventor
피터 존스톤
헤르첼 게르스타인
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20150001757A publication Critical patent/KR20150001757A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR20147028987A 2012-03-28 2013-03-28 기저 인슐린 요법 Withdrawn KR20150001757A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US61/616,768 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US61/619,641 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US61/624,598 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US61/645,909 2012-05-11
US201261701911P 2012-09-17 2012-09-17
US61/701,911 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (1)

Publication Number Publication Date
KR20150001757A true KR20150001757A (ko) 2015-01-06

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147028987A Withdrawn KR20150001757A (ko) 2012-03-28 2013-03-28 기저 인슐린 요법

Country Status (13)

Country Link
US (1) US20150065421A1 (enExample)
EP (1) EP2830650A1 (enExample)
JP (1) JP2015512908A (enExample)
KR (1) KR20150001757A (enExample)
CN (1) CN104334183A (enExample)
AU (1) AU2013241776B2 (enExample)
CA (1) CA2865823A1 (enExample)
HK (1) HK1201155A1 (enExample)
IN (1) IN2014KN02335A (enExample)
MX (1) MX2014011687A (enExample)
RU (1) RU2014143271A (enExample)
SG (1) SG11201405433XA (enExample)
WO (1) WO2013144273A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US20190357853A1 (en) * 2018-05-24 2019-11-28 Lizheng Shi Diabetes risk engine and methods thereof for predicting diabetes progression and mortality

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
PH12012502524A1 (en) * 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy

Also Published As

Publication number Publication date
RU2014143271A (ru) 2016-05-20
SG11201405433XA (en) 2014-10-30
WO2013144273A1 (en) 2013-10-03
AU2013241776A1 (en) 2014-10-16
CN104334183A (zh) 2015-02-04
IN2014KN02335A (enExample) 2015-05-01
EP2830650A1 (en) 2015-02-04
HK1201155A1 (en) 2015-08-28
US20150065421A1 (en) 2015-03-05
JP2015512908A (ja) 2015-04-30
MX2014011687A (es) 2015-05-11
AU2013241776B2 (en) 2017-11-02
CA2865823A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
EP3275438B2 (en) Methods of preventing cardiovascular events in residual risk dyslipidemic populations
Goldberg et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Scobie et al. Fast facts: diabetes mellitus
CN115279395A (zh) 替尔泊肽的治疗用途
AU2013241776B2 (en) Basal insulin therapy
CN116867505A (zh) 替西帕肽治疗方法
Landgraf et al. Therapy of type 2 diabetes
Lind et al. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)
EP3544682A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
AU2018283781B2 (en) Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus
Yozgat et al. Short-term efficacy of ORS formulation and propranolol regimen in children with POTS
Ead Glycemic control and surgery—optimizing outcomes for the patient with diabetes
Azeez Present State and Perspectives of Type 2 Diabetes Management
Nepomnyashchaya TYPE 2 Diabetes mellitus: Diagnostics, clinic, treatment and management features
Hudson et al. Diabetes in older adults
Ilie The endocrine pancreas and diabetes mellitus
Das et al. Pathophysiology and Clinical Therapeutic Aspects of Diabetes
Class et al. Patent application title: BASAL INSULIN THERAPY Inventors: Peter Johnston (Bridgewater, NJ, US) Hertzel Gerstein (Hamilton, CA) Hertzel Gerstein (Hamilton, CA)
Hiremath Handbook Of Perioperative Care Of Adult Diabetes Patients: Diabetes Care–Before, During And After Surgery
Baby et al. Prescribing pattern of antidiabetic drugs for type 2 diabetic in tertiary care teaching hospital
Tanaka et al. Effects of fixed-dose mitiglinide/voglibose combination on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial
Plourde Saxenda in the management of obesity in a type 2 diabetes mellitus patient: a case report
Seetho et al. The clinical management
Brown et al. PCDS report from the American Diabetes Association’s 77th Scientific Sessions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20161011

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid